Schmolling J, Renke K, Richter O, Pfeiffer K, Schlebusch H, Höller T
Department of Obstetrics, University of Bonn, Germany.
Ther Drug Monit. 2000 Oct;22(5):582-8. doi: 10.1097/00007691-200010000-00013.
Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone, another antiarrhythmic agent used in the treatment of fetal tachyarrhythmia, and to assess the effect of an elevated umbilical venous pressure (UVP) on the transfer rate. Isolated lobules of 16 human placentas were dually perfused after spontaneous delivery or caesarean section. The transplacental transfer (area under the curve in the maternal compartment [maternal AUC], area under the curve in the fetal compartment [fetal AUC], kinetic parameters) of digoxin, flecainide, and amiodarone was calculated after these drugs were added to the maternal circuit. In five experiments, the effect of increased UVP on the transplacental transfer rate was assessed by elevating the UVP by 10 cm H2O. Flecainide efflux out of the maternal compartment was significantly greater than that of digoxin (maternal AUC 57.4% +/- 5.1 %/min vs 73.9% +/- 1.5%/min), whereas the flecainide influx into the fetal circulation was smaller (fetal AUC 9.3% +/- 4.1%/min vs 11.5% +/- 2.0%/min). Only in 50% of the experiments were the smallest amounts of amiodarone detectable in the fetal compartment. An elevation of the UVP reduced the influx of digoxin and flecainide into the fetal compartment (fetal AUC) from 11.5% +/- 2.0%/min to 7.4% +/- 1.9%/min and from 9.3% +/- 4.1% to 4.7% +/- 1.4%/min, respectively. Materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone decreases in this sequence. Fetal cardiac insufficiency accompanied by an elevation of the UVP might reduce the transplacental transfer of these drugs, although no significant difference could be found between the reduction of transfer of digoxin and flecainide.
临床观察表明,氟卡尼可能比地高辛更容易通过胎盘,并且在胎儿水肿的情况下,其转运受干扰的程度比地高辛小。本研究的目的是比较地高辛、氟卡尼和胺碘酮(另一种用于治疗胎儿心律失常的抗心律失常药物)的母胎经胎盘转运情况,并评估脐静脉压(UVP)升高对转运速率的影响。在自然分娩或剖宫产术后,对16个人类胎盘的分离小叶进行双灌注。将地高辛、氟卡尼和胺碘酮添加到母体循环中后,计算它们的经胎盘转运情况(母体隔室曲线下面积[母体AUC]、胎儿隔室曲线下面积[胎儿AUC]、动力学参数)。在五个实验中,通过将UVP升高10 cm H2O来评估UVP升高对经胎盘转运速率的影响。氟卡尼从母体隔室的流出量显著大于地高辛(母体AUC为57.4%±5.1%/分钟,而地高辛为73.9%±1.5%/分钟),而氟卡尼进入胎儿循环的流入量较小(胎儿AUC为9.3%±4.1%/分钟,而地高辛为11.5%±2.0%/分钟)。仅在50%的实验中,在胎儿隔室中可检测到最少量的胺碘酮。UVP升高使地高辛和氟卡尼进入胎儿隔室的流入量(胎儿AUC)分别从11.5%±2.0%/分钟降至7.4%±1.9%/分钟,从9.3%±4.1%降至4.7%±1.4%/分钟。地高辛、氟卡尼和胺碘酮的母胎经胎盘转运按此顺序降低。伴有UVP升高的胎儿心脏功能不全可能会降低这些药物的经胎盘转运,尽管地高辛和氟卡尼转运减少之间未发现显著差异。